HU Group’s wholly-owned subsidiary Fujirebio has launched the Lumipulse G pTau 181 Plasma assay for fully automated blood-based Alzheimer’s disease (AD) biomarker testing.

The new chemiluminescent enzyme immunoassay (CLEIA) assay will be used with the fully automated LUMIPULSE G immunoassay system for the quantitative measurement of Tau phosphorylated at threonine 181 (pTau 181) in human plasma.

Available for research use only, the assay will allow clinical research specialists and researchers to further study the marker’s clinical utility on the Lumipulse platform.

Fujirebio president and CEO Goki Ishikawa said: “The projected increase in the number of people suffering from dementia poses significant public health challenges worldwide, of which early diagnosis will be of particular importance.

“Fujirebio is rising to this challenge with the availability of a fully automated plasma pTau 181 assay on our well recognised LUMIPULSE G platform. This breakthrough opens another new chapter in the field of neurodegeneration testing.”

The company stated that the new Lumipulse G pTau 181 Plasma assay complements four key cerebrospinal fluid (CSF) assays, which include Aβ1-42, Aβ1-40, tTau and pTau 181.

These assays are already available on the LUMIPULSE G platform and have the capability to provide essential information regarding the amyloid and tau pathology presence in neurodegenerative disease.

The plasma pTau 181 marker streamlines patient eligibility for clinical trials and monitors patients for future treatments.

It also has the ability to further advance the development of disease-modifying treatments.

With the Diagnostics Accelerator at the Alzheimer’s Drug Discovery Foundation (ADDF) and Flanders Innovation & Entrepreneurship’s (VLAIO) support, the Lumipulse G pTau 181 Plasma assay’s development will be accelerated.